Randomised, double blind, placebo controlled comparison of ginkgo biloba and acetazolamide for prevention of acute mountain sickness among Himalayan trekkers: The prevention of high altitude illness trial (PHAIT)

BMJ

Volumn 328, Issue 7443, 2004, Pages 797-

  Gertsch, Jeffrey H ^a   Basnyat, Buddha ^b   Johnson, E William ^c   Onopa, Janet ^d   Holck, Peter S ^d  

^a MARICOPA MEDICAL CENTER   (United States)

^b Himalayan Rescue Association   (Nepal)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF HAWAII   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; GINKGO BILOBA EXTRACT; OXYGEN; PLACEBO;

ADOLESCENT; ADULT; AGED; ALTITUDE DISEASE; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GINKGO BILOBA; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; MOUNTAINEERING; PHYTOTHERAPY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; CLINICAL FEATURE; DISEASE SEVERITY; DRUG MIXTURE; HEADACHE; HUMAN EXPERIMENT; INCIDENCE; NORMAL HUMAN; OUTCOMES RESEARCH; OXYGEN BLOOD LEVEL; PRIORITY JOURNAL; PROPHYLAXIS; SCORING SYSTEM;

ACETAZOLAMIDE; ADOLESCENT; ADULT; AGED; ALTITUDE SICKNESS; DOUBLE-BLIND METHOD; FEMALE; GINKGO BILOBA; HUMANS; MALE; MIDDLE AGED; MOUNTAINEERING; PHYTOTHERAPY; PROSPECTIVE STUDIES;

EID: 1842506452     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.38043.501690.7C     Document Type: Article

References (18)

1. Hackett PH, Roach RC. High altitude illness. N Engl J Med 2001; 345: 107–14.
2. Basnyat B. Altitude sickness. In: Rakel RE, Bope ET,eds. Conn's current therapy. Philadelphia: WB Saunders, 2001: 1166–9.
3. Roncin JP, Schwartz F, D'Arbigny P. EGb 761 in control of acute mountain sickness and vascular reactivity to cold exposure. Aviat Space Environ Med 1996; 67: 445–52.
4. Gertsch JH, Seto TB, Mor J, Onopa J. Ginkgo biloba for the prevention of severe acute mountain sickness starting one day before rapid ascent. High Alt Med Biol 2002; 2: 110.
5. Leadbetter GW, Maakestad K, Olson S, Hackett PH. Ginkgo biloba reduces incidence and severity of acute mountain sickness. Abstracts from the 12th international hypoxia symposium, Jasper, Alberta, Canada, March 10–14, 2001. High Alt Med Biol 2001; 2: 110.
6. Chow TK, Browne VA, Heileson HL, Wallace DR, Anholm JD. Comparison of Ginkgo biloba versus acetazolamide in the prevention of acute mountain sickness. Med Sci Sports Exerc 2002; 34: S246.
7. Leadbetter GW, Hackett PH, Maakestad K, Tissot-Van Patot M, Olson S, Keyes L, et al. Comparison of Ginkgo biloba, acetazolamide, and placebo for prevention of acute mountain sickness. Abstracts from the 13th international hypoxia symposium, Banff, Alberta, Canada, February 19–22, 2003. High Alt Med Biol 2003; 3: 455.
8. Moraga F, Flores A, Zapata J, Ramos P, Madariaga M, Serra J. Ginkgo biloba decreases acute mountain sickness (AMS) at 3700 m. Abstracts from the 13th international hypoxia symposium, Banff, Alberta, Canada, February 19–22, 2003. High Alt Med Biol 2003; 3: 453.
9. Le Bars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF for the North American EGb Study. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. JAMA 1997; 278: 1327–32.
10. Bailey DM, Davies B. Acute mountain sickness: prophylactic benefits of antioxidant vitamin supplementation at high altitudes. High Alt Med Biol 2001; 2: 21–29.
11. Roach RC, Bartsch P, Hackett PH, Oelz O. The Lake Louise AMS Scoring Consensus Committee. The Lake Louise acute mountain sickness scoring system. In: Sutton JR, Coates G, Huston CS,eds. Hypoxia and molecular medicine: proceedings of the 8th international hypoxia symposium, 9–13 Feb, 1993; Lake Louise, Alberta, Canada. Burlington, VT: Queen City Printers, 1993: 272–4.
12. Bartsch P, Muller A, Hofstettler D, Maggiorini M, Vock P, Oelz O. AMS and HAPE scoring in the Alps. In: Sutton JR, Houston CS, Coates G,eds. Hypoxia and molecular medicine: proceedings of the 8th international hypoxia symposium, Lake Louise, Canada. Burlington, VT: Queen City printers, 1993: 265–71.
13. Maggiorini M, Muller A, Hofstetter D, Bartsch P, Oelz O. Assessment of acute mountain sickness by different score protocols in the Swiss Alps. Aviat Space Environ Med 1998; 69: 1186–92.
14. Murdoch DR. Symptoms of infection and altitude illness among hikers in the Mount Everest region of Nepal. Aviat Space Environ Med 1995; 66: 148–51.
15. Chen X, Salwinski S, Lee TJ. Extracts of Ginkgo biloba and ginsenosides exert cerebral vasorelaxation via a nitric oxide pathway. Clin Exp Pharmacol Physiol 1997; 24: 958–9.
16. Hackett PH, Rennie D, Levine HD. The incidence, importance, and prophylaxis of acute mountain sickness. Lancet 1976; 2: 1149–54.
17. Basnyat B, Gertsch JH, Johnson EW, Castro-Marin F, Inoue Y, Yeh C. Efficacy of low-dose acetazolamide (125 mg BID) for the prophylaxis of acute mountain sickness. High Alt Med Biol 2003; 4: 45–52.
18. Dumont L, Mardirosoff C, Tramer MR. Efficacy and harm of pharmacological prevention of acute mountain sickness: quantitative systematic review. BMJ 2000; 321: 267–72.